ADMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADMA Biologics Inc is not a strong buy at the moment for a beginner investor with a long-term strategy. While hedge funds are increasing their positions significantly, the company's financial performance shows declining net income and EPS, which are critical for long-term growth. Additionally, technical indicators suggest bearish trends, and there are no recent positive news or strong trading signals to support an immediate buy decision.
The MACD is below 0 and negatively expanding, indicating bearish momentum. RSI is neutral at 39.833, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 15.462, with support at 14.754 and resistance at 16.171.
Hedge funds are significantly increasing their positions, with a 719.51% increase in buying over the last quarter. Gross margin has improved by 18.42% YoY, indicating operational efficiency.
Net income dropped by 55.87% YoY, and EPS fell by 55.56%, indicating declining profitability. No recent news or significant insider activity to support a positive outlook. Technical indicators are bearish, and there are no strong trading signals.
In Q4 2025, revenue increased by 18.39% YoY to $139.16M, but net income dropped by 55.87% YoY to $49.38M. EPS also declined by 55.56% to $0.20. Gross margin improved to 63.78%, up 18.42% YoY, but the decline in net income and EPS raises concerns about profitability.
No recent analyst rating or price target changes are provided. Wall Street sentiment is unclear based on the available data.
